Carvedilol for Heart Failure: Clinical Trials in Progress

摘要: Carvedilol is the first and currently only beta-blocker licensed for use in heart failure. Consequently, it which greatest patient-years experience exists. The total clinical trial reported so far with carvedilol failure amounts to over 2,000 patients but trials of are running that will include almost 10,000 more patients. programme includes re-confirmation benefits beta-blockers post-infarction setting (CAPRICORN) extension evidence benefit asymptomatic left ventricular dysfunction (CARMEN) severe (COPERNICUS). also tests exciting radically new concepts management as well addressing real, practical, needs. Studies such CARMEN CAFE should re-examine role ACE inhibitors (in very mild failure) digoxin (for atrial fibrillation) an attempt reduce polypharmacy. Other studies address issues diastolic effects treatment on ischaemic/hibernating myocardium (CHRISTMAS). However, most important study practice COMET study, comparing metoprolol a head-to-head comparison. This compare different betablockers mortality any addresses one hotly debated surrounding recent spate positive Metaanalysis including all does not disprove concept class effect. point estimates show trend greater combined data-set than metoprolol. powered confirm whether this difference real.